Sector News

Screen addicts, rejoice: J&J Vision to roll out contact lenses designed for digital device fatigue

June 19, 2022
Life sciences

With adults and children spending more time in front of phones, tablets and computer screens, contact lenses are racing to catch up with growing reports of eye fatigue caused by digital devices. And by the end of this year, Johnson & Johnson Vision plans to roll out a new set of daily contacts designed specifically for the task.

The company announced its Acuvue Oasys Max 1-Day lenses have received regulatory green lights in the U.S., Canada and Europe and are slated to become available this fall.

Offered in spherical and multifocal versions, the Oasys Max contacts are described as “a premium range” of daily disposable lenses and are designed for all-day comfort when faced with long stretches of screen time.

According to J&J, adults are now spending an average of 13 hours per day in front of digital devices—a number that’s jumped 35% since 2019, as the COVID-19 pandemic forced many to seek out their entertainment from within the home.

Meanwhile, younger contact lens wearers now spend about nine hours per day looking at a screen, where prolonged attention can cut down on blinking by as much as 60%, which ultimately disrupts the thin film of tears lubricating the eye and can lead to more dryness and discomfort.

The company said 71% of surveyed eye care professionals have reported patient complaints of strain and fatigue due to increased screen time, and that 75% of patients said they wanted increased comfort in their contact lenses.

“Our lives have evolved significantly over the past few years creating increased demands on our eyes,” said Peter Menziuso, company group chairman of J&J Vision, which has sought to address a number of long-held complaints by contact lens wearers in recent years.

This past March, the FDA approved a J&J contact lens infused with an allergy-fighting antihistamine to help fight off eye itchiness caused by pollen, grass, pet dander or dust.

The company has estimated about 40% of contact wearers also suffer from conjunctivitis. And while deeply rubbing an eye while wearing a lens is obviously meant to be avoided, even the use of certain medicated eye drops can interfere with the contacts’ vision correction—forcing users to juggle between the two during allergy season.

Separately, J&J partnered with Japanese manufacturer Menicon last year on contacts designed to slow the progression of childhood nearsightedness, using multifocal lenses that aim to tamp down growth in the size of the eye, which is the main cause of myopia.

By Conor Hale


comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach